Welcome to our dedicated page for Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) news (Ticker: CYTO), a resource for investors and traders seeking the latest updates and insights on Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) stock.
Altamira Therapeutics Ltd., formerly known as Auris Medical, is a pioneering company dedicated to developing therapeutics that address significant unmet medical needs. Founded in 2003 and headquartered in Hamilton, Bermuda, with principal operations in Basel, Switzerland, Altamira Therapeutics trades on the NASDAQ Capital Market under the symbol “CYTO”.
Altamira is actively engaged in three primary areas:
- RNA Therapeutics: Utilizing innovative platforms such as OligoPhore™ and SemaPhore™, the company focuses on developing RNA-based therapies targeting extrahepatic sites. These platforms, currently in the preclinical stage, leverage proprietary peptides to form nanoparticles capable of delivering therapeutic RNA to tissues affected by conditions like solid tumors and inflammation.
- Nasal Sprays: The commercially available Bentrio™ nasal spray offers protection against airborne viruses and allergens, while AM-125, which is in Phase 2 clinical trials, targets the treatment of vertigo.
- Inner Ear Disorders: Altamira is progressing with Phase 3 development of Keyzilen® and Sonsuvi® for the intratympanic treatment of tinnitus and hearing loss, respectively.
Altamira Therapeutics is committed to advancing its pipeline through rigorous research and strategic collaborations. Recently, the company has made significant strides with its RNA therapies, as highlighted in studies such as Huang et al. (2021) and Strand et al. (2019), demonstrating the potential of targeting KRAS mutations in cancer. Moreover, ongoing research in peptide-based nanoparticles and NF-κB subunit targeting shows promising applications in inflammatory diseases and cancer treatment.
In the field of nasal sprays, Altamira's Bentrio™ has shown efficacy in clinical trials, with recent studies like Becker et al. (2024) validating its use in protecting against seasonal allergic rhinitis.
Financially, Altamira Therapeutics has reclassified its Bentrio business as discontinued operations, focusing its resources on advancing its core therapeutic areas. The company's investor communications emphasize its forward-looking strategy and commitment to innovation.
Stay updated with the latest news and developments from Altamira Therapeutics by visiting their official website and connecting through their social media channels.
Altamira Therapeutics (NASDAQ:CYTO) announced reaching the enrollment midpoint in its COVAMID trial of Bentrio nasal spray for acute COVID-19. The trial aims to evaluate Bentrio's effectiveness in reducing SARS-CoV-2 viral load, alleviating symptoms, and decreasing hospital admissions. A total of 136 COVID-19 patients will participate in a randomized study. Positive in vitro results have already been observed, with plans to expand the trial to North Macedonia and possibly India. Completion is anticipated by Q3 2022.
Altamira Therapeutics (NASDAQ:CYTO) announced key developments during its investor call on April 12, 2022. The company is pivoting towards RNA therapeutics with its OligoPhore and SemaPhore platforms, having made significant progress, including the completion of enrollment in the Bentrio house dust mite trial and the launch of a clinical trial for acute COVID-19. Financially, Altamira reported a net loss of CHF 17.4 million for 2021, while revenues reached CHF 0.1 million. The company has plans to divest its legacy business and enhance its RNA capabilities, aiming for an FDA IND in 2023.
Altamira Therapeutics (NASDAQ: CYTO) announced the publication of a study in the International Journal of Molecular Sciences confirming the efficacy and safety of its drug-free nasal spray, Bentrio, against the SARS-CoV-2 Delta variant. The study demonstrated a reduction in viral titer by up to 99% and highlighted Bentrio's potential as a prophylactic treatment. The company is also conducting a COVAMID clinical trial for acute COVID-19 patients. Bentrio is already available in parts of Europe and aims for broader distribution.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced a conference call for April 12, 2022, at 8:00 a.m. ET to discuss its full-year 2021 earnings. The session will be accessible via teleconference or webcast, including audio and presenter-controlled slides. The company focuses on developing therapeutics addressing unmet medical needs across various platforms, including RNA therapeutics and nasal sprays. The replay of the call will be available for two weeks following the initial event.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) has completed patient enrollment in its Bentrio™ trial for house dust mite (HDM) allergic rhinitis, involving 37 patients. The trial aims to assess Bentrio's efficacy in treating perennial allergic rhinitis under controlled HDM exposure, with top-line results expected in Q2 2022. The company's CEO emphasized the importance of Bentrio, following positive outcomes in previous studies. Notably, HDM allergies affect millions globally and can severely impact quality of life.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced promising in vitro results for its Bentrio™ nasal spray against the Omicron variant of SARS-CoV-2. The study showed that prophylactic use of Bentrio prior to viral exposure reduced viral titer by 89.5% within 24 hours, compared to saline controls. Even when applied after peak viral levels, significant reductions of 87.1%COVAMID, is underway to further evaluate Bentrio's efficacy in COVID-19 patients.
Altamira Therapeutics (NASDAQ:CYTO) has received approval to initiate the COVAMID clinical trial evaluating Bentrio™ as a treatment for COVID-19. The study will involve 136 confirmed cases, randomized into groups receiving Bentrio™, placebo, or no treatment, over a 10-day period. Based on interim analysis, participants may increase to 180. Bentrio™ aims to reduce SARS-CoV-2 viral load and alleviate symptoms. Earlier studies indicated over a 99% viral load reduction with Bentrio™. The trial will begin in Bulgaria, with potential expansion to two other countries.
Altamira Therapeutics (NASDAQ:CYTO) has secured an exclusive licensing agreement with Nuance Pharma for its nasal spray, Bentrio™, targeting the Chinese Mainland, Hong Kong, Macau, and South Korea. This deal includes a $1 million upfront payment, with potential milestone payments up to $23.5 million. Nuance will manage local production and will pay royalties based on net sales once production starts. The collaboration aims to address the significant market need for allergy and virus protection, especially given the prevalence of allergic rhinitis affecting 246 million in the region.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) has completed patient enrollment in Part B of the Phase 2 'TRAVERS' clinical trial for AM-125, an intranasal formulation of betahistine aimed at treating acute vertigo. This trial involves 75 patients and seeks to demonstrate efficacy through the Tandem Romberg test. Following positive interim results from Part A, the company anticipates announcing top-line results by Q2 2022. AM-125 offers higher bioavailability than oral betahistine and addresses a significant medical need affecting many U.S. adults over 40.
Altamira Therapeutics Ltd. (NASDAQ:CYTO) announced an expansion of its marketing and distribution agreement for Bentrio™ with Wellesta Holding Pte Ltd, adding the Philippines and Morocco to its existing markets. This agreement now covers a total of eight countries, aiming to leverage Wellesta's experience in these new regions, which represent significant population bases: approximately 110 million in the Philippines and 37 million in Morocco. Bentrio™ is a drug-free nasal spray designed to protect against airborne viruses and allergens.
FAQ
What is the current stock price of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO)?
What is the market cap of Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda) (CYTO)?
What areas of therapeutics does Altamira Therapeutics focus on?
What are the main products of Altamira Therapeutics?
Where is Altamira Therapeutics headquartered?
What is the stock symbol for Altamira Therapeutics?
What recent achievements has Altamira Therapeutics made in RNA therapeutics?
What stage are the inner ear disorder treatments in?
How does the OligoPhore™ platform work?
What are the recent clinical trial results for Bentrio™?
What is the significance of recent financial reclassifications for Altamira?
How can investors stay updated with Altamira Therapeutics?
